HFSA 2022
ANNUAL SCIENTIFIC MEETING
WHERE HEART FAILURE TEAMS GATHER

Gaylord National Harbor, Washington, DC

September 30 – October 3, 2022

2022 Final Program
Merck Medical Forums

Join us for an interactive lecture

Merck cordially invites you to attend the medical education event listed below for US healthcare professionals and US healthcare business professionals only. Merck is sponsoring this event and the speaker is presenting on behalf of Merck. The event is a non-CME program. Information presented in this event is consistent with FDA guidelines.

SPEAKER BIO: Javed Butler, MD, MPH, MBA is President of Baylor Scott and White Research Institute in Dallas, TX and a Professor of Medicine at the University of Mississippi, Jackson, MS. Dr. Butler attended medical school at Aga Khan University in Karachi, Pakistan. He completed his residency at Yale University and his fellowships in Cardiovascular Disease and Heart Failure and Transplant at Vanderbilt University and in Cardiac Imaging at Massachusetts General Hospital, Harvard University. He received his MPH from Harvard School of Public Health and his MBA from Emory University Goizueta Business School. He is board certified in Cardiovascular Medicine, Nuclear Cardiology and Advanced Heart Failure and Cardiac Transplantation. Dr. Butler is a Fellow of the American Heart Association, the American College of Cardiology, the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.

Treatment Considerations for Patients With HFrEF and Select Updates From the 2022 HF Guideline

Learning objectives:

• Highlight the impact of HFrEF in the United States.
• Review a treatment option for reducing the risk of HFH and CV death in patients with HFrEF.
• Provide an overview of selected updates to the 2022 AHA/ACC/HFSA Guideline for the management of HF.

Monday, October 3, 2022
6:45 AM
Speaker: Dr. Javed Butler, MD

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-VER-02323 09/22
# Table of Contents

- President’s Message: 2
- HFSA Leadership: 3
- Corporate Members: 4
- General Meeting Information – In-Person: 5-6
- General Meeting Information – Virtual: 9
- Health & Safety Protocols: 10
- Networking Guide: 12-13
- Attendee Contests: 14
- Supporting Companies: 15
- 2022 Award Recipients: 16
- Schedule at a Glance: 18-22
- Satellite Symposia (CEUs): 23
- Industry Expert Theaters (No CEUs): 24-27
- Contemporary Forums (No CEUs): 28-30
- Clinical Trial Central: 31-33
- Emerging Innovations Row: 34-35
- Exhibitor Floorplan + Directory at a Glance: 36
- Exhibitor Descriptions: 37-42
- Gaylord National Harbor Hotel Map: 43-44
President’s Message

HFSA 2022 President’s Message

Welcome to the 26th Annual Scientific Meeting (ASM) of the Heart Failure Society of America!

Drs. David Lanfear (Chair), Rob DiDomenico, Daniel Garry, Cheryl Westlake (Co-Chairs), the rest of the members of the planning committee, and HFSA staff have put together a wonderful meeting. In 2019, ASM adopted the tagline “Where Heart Failure Teams Gather," and that remains true of this meeting as well. I’m thrilled that our community has come together, once again, to learn, share ideas, celebrate innovations, and welcome early career professionals into the HFSA family.

We have a lot to be excited about, even before the meeting begins, including the following:

- More than 400 abstracts
- More than 50 exhibitors
- 39 Scientific Sessions
- 3 Plenary Sessions
- 8 Industry Expert Theaters
- 6 Contemporary Forums
- 7 Satellite Symposia
- 4 Workshops

This year, we also have a special initiative for the early career attendees of all disciplines. Specifically, you will have access to a new Professionals-in-Training Lounge, more affectionately called “The PIT.” Not just a lounge, The PIT will be a forum for discussions and roundtables about content that is geared towards an early career audience. The PIT will also have a message board so that those of you more senior in your career can leave words of advice for the next generation of heart failure professionals.

This year also marks the first time we’ve had three Plenary Sessions, one per morning to start each day. The Presidential Plenary on Saturday will include my Presidential address, a welcome from incoming HFSA President, Dr. John Teerlink, and an Awards ceremony. This will be immediately followed by a Keynote Address about innovation in heart failure by Drs. Michael Bristow and Gary Gibbons, esteemed leaders in our field, and conclude with a panel discussion. The subsequent Plenary sessions are equally exciting, with one featuring the results of Late Breaking Clinical Trials (Sunday) and one focused on xenotransplantation (Monday).

As a tip, the best way for you to plan your on-site agenda is to download the HFSA ASM 2022 mobile app, which is available in the app stores. For those of you on the Twitterverse, take advantage of our Tweet Up and onsite selfie spots, and please remember to include #HFSA2022 on all your tweets.

Finally, I encourage you to get involved while in DC. Attend the sessions and ask questions from the audience, engage with an abstract presenter, direct message a Social Media Catalyst, visit our exhibitors, participate in the scheduled networking opportunities, and speak with Board and committee members about their roles. Also, please seek out a new member and help welcome them to the HFSA family.

I wish all our ASM attendees, presenters, exhibitors, and sponsors a productive and fun meeting.

Mark Drazner, MD, MSc, FHFSAPresident, HFSA 2021-2022
About HFSA

HFSA’s mission is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy.

The Heart Failure Society of America’s vision is to significantly reduce the burden of heart failure.

2022 Board of Directors

2022 Elected Officers

President: Mark Drazner, MD, MSc, FHFA
President Elect: John Teerlink, MD, FHFA
Secretary: Jim Fang, MD, FHFA
Treasurer: Mona Fiuzat, PharmD, FHFA
Immediate Past President: Nancy M. Albert, PhD, RN, FHFA

Board Members

Mike Felker, MD, FHFA
Michael Givertz, MD, FHFA
Michelle Kittleson, MD, PhD
Ken Margulies, MD, FHFA
Colleen McIlvennan, PhD, DNP, ANP, FHFA
Nancy Sweitzer, MD, PhD, FHFA

2022 ASM Program Committee

2022 Chair: David Lanfear, MD, FHFA
2022 Co-Chair: Rob DiDomenico, PharmD, FHFA
2022 Co-Chair: Daniel Garry, MD, PhD, FHFA
2022 Co-Chair: Cheryl Westlake, PhD, RN, FHFA
Akshay Desai, MD, MPH, FHFA
Zachary Cox, PharmD, FHFA
Windy Alonso, PhD, RN, FHFA
Prateeti Khazanie, MD, MPH, FHFA
Amrut Ambardekar, MD, FHFA
Timothy Fendler, MD
Ashley Hardin, MD
Line Kemeyou, MD, FHFA
Melissa Owen, PhD, RN, FHFA
Jo Ellen Rodgers, PharmD, FHFA
Emily Tsai, MD, FHFA
Leslie Cooper, MD, FHFA
Robert Malloy, NP
Nosheen Reza, MD, FHFA
Kelly Rogers, PharmD
Esther Vorovich, MD
Payman Zamani, MD, FHFA
Gaylord National Resort & Convention Center

All in-person meeting activities will be held in the Gaylord National Resort & Convention Center. All virtual meeting activities will be held in the Virtual Meeting Platform accessible to registered attendees at meeting.hfsa.org (coming soon). Additional meeting information can be found in the following pages.

All schedules are listed in Eastern Standard Time.

Registration Hours

The registration area will be located at the Ballroom Level Convention Center Pre-Function Space of the Gaylord National Resort & Convention Center.

Friday, September 30 | 10:00 AM – 7:00 PM
Saturday, October 1 | 6:30 AM – 6:00 PM
Sunday, October 2 | 6:30 AM – 5:30 PM
Monday, October 3 | 6:30 AM – 9:00 AM

Included in Registration Fee

In-Person + Virtual
Access to all meeting activities including in-person live sessions, exhibit hall, networking receptions, and more at the fabulous Gaylord National Resort. In addition, in-person attendees will also have access to the same virtual offerings such as livestreamed sessions if you choose to enjoy a session from your hotel room, an outdoor space, or elsewhere, and OnDemand recordings.

Virtual Only
Select livestream sessions and session recordings available OnDemand post-meeting. Please view the Schedule at a Glance (page 18) or the Virtual Meeting Platform at meeting.hfsa.org (coming soon) for virtual sessions.

Speaker Ready Room

Chesapeake 6
Friday, September 30 | 7:00 AM – 7:45 PM
Saturday, October 1 | 7:00 AM – 7:15 PM
Sunday, October 2 | 7:00 AM – 5:15 PM
Monday, October 3 | 7:00 AM – 11:15 AM

Exhibit Hall Hours

Friday, September 30 | 6:00 PM – 7:30 PM
Saturday, October 1 | 11:35 AM – 1:35 PM and 5:30 PM – 7:00 PM
Sunday, October 2 | 12:00 PM – 2:00 PM
Monday, October 3 | CLOSED

Poster Viewing Sessions & Oral Poster Session

Co-Moderated by Journal of Cardiac Failure

ePoster Hub and Poster Theater – Exhibit Hall

Opening Reception

Friday, September 30 | 6:00 PM – 7:30 PM | Exhibit Hall

Join us as we welcome you to the HFSA Annual Scientific Meeting 2022! The Opening Reception is a great way to start your first day – where heart failure teams gather.

Press Room

Chesapeake 12
Saturday, October 1 | 7:00 AM – 5:00 PM
Sunday, October 2 | 7:00 AM – 5:00 PM
Monday, October 3 | 7:00 AM – 12:00 PM
General Meeting Information – In-Person

Wi-Fi
Complimentary Wi-Fi is available in the education sessions.
Network Name: HFSA Annual Meeting
Username: HFSA2022
Password: HFSA2022
Courtesy of Bristol Myers Squibb

Dress Code
Meeting attire is business casual. We suggest you dress in layers as meeting room temperatures often vary.

Children
The HFSA does not allow children under the age of 16 in the Exhibit Hall at any time. Due to limited seating capacity and the technical nature of the program, children (under age 16) are not allowed into the scientific sessions.

Special Needs
The HFSA strives to hold meetings that are accessible to all. Please tell us what you require to help make your participation more enjoyable and meaningful. For questions and more information, contact Lindsey Best at lbest@gmimeetings.com.

No Smoking Policy
HFSA and the Conference Center prohibit smoking in all meeting and hotel areas. Thank you for your cooperation.

Questions?
Visit the HFSA Membership Booth or the Registration Desk with questions or email HFSA staff at info@hfsa.org. Emailed responses may be delayed due to staff being onsite at the meeting.

Food Policy
The Physician Payment Sunshine Act, part of the Affordable Care Act, requires that manufacturers of drug and devices report to CMS certain payments and items of value given to physicians. These items of value include meals at CME activities, such as this annual meeting. For this reason, the following food and refreshments provided at the HFSA Annual Scientific Meeting will be paid for out of registration fees and the HFSA operating budget: the Opening Reception, Poster Receptions, early morning refreshments, lunches, and coffee breaks. All coffee and tea stations, aside from continental breakfast areas will be in the Exhibit Hall.

Screen Recording and Photography Policy
HFSA staff members, HFSA photographers, HFSA videographers, preapproved videographers, and pre-approved photographers, are the only ones authorized to photograph and film events and virtual educational sessions throughout the meeting. Any photographs, screen shots, screen recordings, and videos taken by our HFSA Staff and HFSA photographers and videographers are used exclusively by HFSA for promotional purposes and continuing education offerings. They may be used in the society’s publications, website, social media accounts, programs, or other HFSA promotional materials. If you are attending a virtual session and you do not wish to be photographed or recorded, please identify yourself via email to HFSA staff at LPoko@hfsa.org.

Liability Statement
The Heart Failure Society of America (HFSA) cannot accept, and hereby specifically disclaims, any liability for death, injury, any loss, cost or expense suffered or incurred by any person if such loss is caused by, arises from or results from the act, default or omission of any person other than an employee or agent of HFSA. In particular, neither HFSA nor its agents can accept, and hereby specifically disclaims, any liability for losses arising from, caused by, or resulting from, the provision or non-provision of services provided by the hotels, companies, or transport operators. Neither HFSA nor its agents can accept, and hereby specifically disclaims, liability for losses suffered by reason of war including threat of war, riots and civil strife, terrorist activity, natural disaster, weather, fire, flood, drought, technical, mechanical or electrical breakdown within any premises visited by delegates and/or participants in connection with the meeting, industrial disputes, government action, regulations or technical problems that affect or may affect the services provided in connection with the meeting. HFSA is not able to warrant and does not warrant that a particular person will appear as a speaker. As a condition to any participation in or attendance at the Annual Scientific Meeting or any function associated or affiliated herewith, each attendee and participant accepts the foregoing Disclaimer.

Complimentary Wi-Fi is available in the education sessions.

Network Name: HFSA Annual Meeting
Username: HFSA2022
Password: HFSA2022
Courtesy of Bristol Myers Squibb

Dress Code
Meeting attire is business casual. We suggest you dress in layers as meeting room temperatures often vary.

Children
The HFSA does not allow children under the age of 16 in the Exhibit Hall at any time. Due to limited seating capacity and the technical nature of the program, children (under age 16) are not allowed into the scientific sessions.

Special Needs
The HFSA strives to hold meetings that are accessible to all. Please tell us what you require to help make your participation more enjoyable and meaningful. For questions and more information, contact Lindsey Best at lbest@gmimeetings.com.

No Smoking Policy
HFSA and the Conference Center prohibit smoking in all meeting and hotel areas. Thank you for your cooperation.

Questions?
Visit the HFSA Membership Booth or the Registration Desk with questions or email HFSA staff at info@hfsa.org. Emailed responses may be delayed due to staff being onsite at the meeting.

Food Policy
The Physician Payment Sunshine Act, part of the Affordable Care Act, requires that manufacturers of drug and devices report to CMS certain payments and items of value given to physicians. These items of value include meals at CME activities, such as this annual meeting. For this reason, the following food and refreshments provided at the HFSA Annual Scientific Meeting will be paid for out of registration fees and the HFSA operating budget: the Opening Reception, Poster Receptions, early morning refreshments, lunches, and coffee breaks. All coffee and tea stations, aside from continental breakfast areas will be in the Exhibit Hall.

Screen Recording and Photography Policy
HFSA staff members, HFSA photographers, HFSA videographers, preapproved videographers, and pre-approved photographers, are the only ones authorized to photograph and film events and virtual educational sessions throughout the meeting. Any photographs, screen shots, screen recordings, and videos taken by our HFSA Staff and HFSA photographers and videographers are used exclusively by HFSA for promotional purposes and continuing education offerings. They may be used in the society’s publications, website, social media accounts, programs, or other HFSA promotional materials. If you are attending a virtual session and you do not wish to be photographed or recorded, please identify yourself via email to HFSA staff at LPoko@hfsa.org.

Liability Statement
The Heart Failure Society of America (HFSA) cannot accept, and hereby specifically disclaims, any liability for death, injury, any loss, cost or expense suffered or incurred by any person if such loss is caused by, arises from or results from the act, default or omission of any person other than an employee or agent of HFSA. In particular, neither HFSA nor its agents can accept, and hereby specifically disclaims, any liability for losses arising from, caused by, or resulting from, the provision or non-provision of services provided by the hotels, companies, or transport operators. Neither HFSA nor its agents can accept, and hereby specifically disclaims, liability for losses suffered by reason of war including threat of war, riots and civil strife, terrorist activity, natural disaster, weather, fire, flood, drought, technical, mechanical or electrical breakdown within any premises visited by delegates and/or participants in connection with the meeting, industrial disputes, government action, regulations or technical problems that affect or may affect the services provided in connection with the meeting. HFSA is not able to warrant and does not warrant that a particular person will appear as a speaker. As a condition to any participation in or attendance at the Annual Scientific Meeting or any function associated or affiliated herewith, each attendee and participant accepts the foregoing Disclaimer.
NEW

DAILY Plenary sessions you don’t want to miss...

- Presidential Plenary Session: The Importance of Innovation in Heart Failure: Perspectives on Scientific, Regulatory, and Funding Initiatives
- Sunday Plenary Session: Late Breaking Clinical Trials
- Monday Plenary Session: Cardiac Xenotransplantation: Where We Are and Where We Are Going

HFSA.ORG/ASM2022
Change the world of heart failure by joining HFSA

Become a Member of HFSA

LEARN!
Access self-paced educational content, gain CE and MOC credits, and attend sessions at HFSA in-person and virtually

INVESTIGATE!
Stay abreast of the latest research and share your own with the HF community through publications, speaking opportunities, and more

NETWORK!
Build professional relationships, connect with mentors, and create new collaborations with colleagues from all HF disciplines

BE A LEADER!
Drive the growth of the HF field by taking on HFSA leadership roles

Learn more about HFSA membership, renew, or join today at www hfsa org/membership
General Meeting Information – Virtual

**All schedules are listed in Eastern Standard Time.**

**Virtual Meeting Platform**
All virtual meeting activities will be held in the Virtual Meeting Platform accessible to registered attendees at meeting.hfsa.org (coming soon).

**HFSA ASM 2022 Mobile App – Coming Soon!**
The official mobile app for the HFSA Annual Scientific Meeting 2022
Enhance your experience at the Heart Failure Society of America’s (HFSA) Annual Scientific Meeting 2022 with the HFSA ASM mobile app! Explore scientific sessions and speakers as you build your own agenda for the meeting; watch some sessions live directly in the app; browse ePosters and learn about intriguing new research; connect with colleagues and peers in live zoom chats; and more!

**Virtual Meeting Platform and ePoster Hall Hours**
The ePosters on the Virtual Meeting Platform are accessible at any time for attendees. Virtual attendees are encouraged to connect with poster presenters and have the ability to send comments or queries to abstract authors.

**Included in Registration Fee**
Virtual Only
Select livestream sessions and session recordings available OnDemand post-meeting. Please view the Schedule at a Glance page 18 or the Virtual Meeting Platform at meeting.hfsa.org (coming soon) for virtual sessions.

**Required Technology**
The Virtual Meeting Platform supports the most current version of the popular browsers (Chrome, Safari, Firefox, etc.) and operating systems as outlined below. Chrome is the preferred browser.

**System OS:**
- Mac OS – Version 10 or later
- iPhone & iPad OS – Version 13 or later
- Windows OS – Version 8 or later
- Android OS – Android 5 or later

**iPad & iPhone:**
- Safari – Version 13 or later

**Windows:**
- Google Chrome – Version 93 or later (recommended)
- Firefox – Version 91 or later

**Android:**
- Google Chrome – Version 81 or later (recommended)

**Questions?**
Technical questions about the platform, including questions about required technology, live cast delays, freezing issues, etc., can be answered here: https://eu.jotform.com/OEP_Support/freeman-virtual-support-portal
The health and safety of attendees and participants at the HFSA Annual Scientific Meeting (ASM) 2022 at the Gaylord National Harbor in Washington, DC from September 30, 2022 - October 3, 2022 is our highest priority. HFSA will continue to monitor the status of COVID-19, particularly the status of local directives at the Gaylord National Harbor, in Prince George’s County and in the state of Maryland.

Frequently Asked Questions

Are masks required onsite at the HSFA Annual Scientific Meeting?
Masks are not required, however, we are supportive of any attendee who wishes to wear a mask while in attendance, and will have disposable masks onsite for their convenience. HFSA will follow any local directives in place at the time of the meeting at the Gaylord National Harbor, in Prince George’s County and in the state of Maryland.

Are vaccinations required to attend HSFA Annual Scientific Meeting?
Vaccinations are not currently required but encouraged. As stated previously, HFSA will follow any local directives in place at the time of the meeting at the Gaylord National Harbor, in Prince George’s County and in the state of Maryland.

Will HFSA offer color coded lanyards to assist attendees in communicating their comfort level with COVID-19?
Yes, registered attendees will be given the option of three colored lanyards at registration:
• Green: Go! Handshakes, high fives and hugs are welcome
• Yellow: Slow! Elbow bumps are more my style
• Red: Stop! I’m keeping my distance, no physical contact

What safety protocol are currently planned for the meeting?
1) COVID-19 vaccinations encouraged
2) Hotel mobile app check-in/out available
3) Screens / computers / printers will be set up at the registration desk to allow for contact-less badge printouts
4) Offering color coded meeting lanyards/badges (red, yellow, green) to easily communicate attendee social distancing preferences onsite
5) Sanitation stations can be found throughout meeting rooms, hallways, and registration areas
6) All sessions and events will be held on-site to minimize need for additional travel

Self-Screening

For the safety of all meeting participants, event staff, and hotel staff, please self-screen for risk factors. If you experience any of the following symptoms, please stream sessions from your hotel room until your symptoms cease and notify a member of HFSA staff at info@hfsa.org. We appreciate your cooperation in making HFSA 2022 a safe and healthy meeting space!

• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Fatigue
• Muscle or body aches
• Headache
• New loss of taste or smell
• Sore throat
• Congestion or runny nose
• Nausea or vomiting
• Diarrhea
The Professionals in Training (PIT) Lounge is THE SPOT at ASM for all professionals who are in the early stage of their career! Complete with programming centered on career development and professional growth, the PIT Lounge can’t be missed. Make a “PIT stop” here to learn, network, and recharge your battery with refreshments and tech charging stations.

Stop by Chesapeake 2
Saturday, October 1
7:45 AM - 4:30 PM
Sunday, October 2
7:45 AM - 4:30 PM
Monday, October 3
8:00 AM - 11:00 AM
Networking Guide – Onsite Attendees

Places to Visit

Membership and Information Booth
Friday, September 30 | 12:00 PM - 6:30 PM | Convention Center Pre-Function
Saturday, October 1 | 7:30 AM - 6:00 PM | Convention Center Pre-Function
Sunday, October 2 | 7:30 AM - 5:00 PM | Convention Center Pre-Function
Monday, October 3 | 7:30 AM - 11:30 AM | Convention Center Pre-Function

Visit the Membership and Information Booth, located on the Ballroom Level near the Potomac Ballroom, to learn about HFSA membership and its benefits. Ask questions about HFSA programs, tools, and resources at this one-stop-shop for all things HFSA and ASM.

HFSA Lounge
Friday, September 30 | 6:00 PM - 7:30 PM | Exhibit Hall
Saturday, October 1 | 11:35 AM - 1:35 PM and 5:30 PM - 7:00 PM | Exhibit Hall
Sunday, October 2 | 12:00 PM - 2:00 PM | Exhibit Hall
Monday, October 3 | CLOSED

Swing by the HFSA Lounge in the Exhibit Hall to connect with peers and colleagues during an existing lineup of receptions and networking activities, such as the Research Reception and Research Corner, and HF Cardiovascular Team Reception. The full schedule of activities is posted outside the lounge.

FHFSA Fellows Lounge
Saturday, October 1 | 9:00 AM - 4:30 PM | Chesapeake 3
Sunday, October 2 | 10:00 AM - 4:00 PM | Chesapeake 3
Monday, October 3 | CLOSED

Join other Fellows of the Heart Failure Society of America in the Fellows Lounge! Learn more about becoming an HFSA Fellow by visiting Hfsa.org/fellowship.

NEW! Professionals In Training (PIT) Lounge
Saturday, October 1 | 7:45 AM - 4:30 PM | Chesapeake 2
Sunday, October 2 | 7:45 AM - 4:30 PM | Chesapeake 2
Monday, October 3 | 8:00 AM - 11:00 AM | Chesapeake 2

The Professionals In Training (PIT) Lounge is THE SPOT at ASM for all professionals who are in the early stage of their career! Complete with programming centered on career development and professional growth, the PIT Lounge can’t be missed. Make a “PIT stop” here to learn, network, and recharge your battery with refreshments and tech charging stations.

Journal of Cardiac Failure Booth
Saturday, October 1 | 9:00 AM - 1:00 PM | Potomac Registration Desk
Sunday, October 2 | 9:30 AM - 3:00 PM | Potomac Registration Desk

Visit the Journal of Cardiac Failure booth just outside of Potomac Ballroom to interact with the talented JCF editorial team. Learn more about what the journal has to offer, best practices on submitting your papers for publication, and how you can become part of the JCF team in the future.

Virtual Lounges
HFSA will host virtual lounges on the virtual meeting platform under the right-hand side menu. The virtual lounges are a great way to network, engage and discuss important topics in heart failure in an informal and relaxed setting.
Receptions/Activities

**Friday, September 30**

**Opening Reception**
6:00 PM - 7:30 PM | Exhibit Hall
Kick off your time at this year’s ASM with our Opening Reception! Gather with old friends, meet up with new colleagues, and get a first-time peek at this year’s Exhibit Hall.

**Research Reception and Research Corner**
6:15 PM - 7:15 PM | Exhibit Hall - HFSA Lounge
Network with professionals focused on research in heart failure alongside members of the HFSA Research Committee. New to this year’s reception is Research Corner – an opportunity for you to ask questions and engage in dialogue about breakthrough research taking a hold of the field.

**Women in HF Reception**
No Food or Beverage Provided
5:30 PM - 6:30 PM | Potomac C
It’s time to celebrate the work being done by women in the field of heart failure! Build new connections alongside members of the HFSA Women in Heart Failure Committee, peers, and colleagues.

*Welcome and Intros: Mahazarin Ginwalla, MD, MS, FACC, FHFSA, Chair, Women in HF Committee*

*Guest Speaker: Dr. Yvonne Cagle - an American physician, professor, retired U.S. Air Force Colonel and former NASA Astronaut*

Sponsored by Platinum ASM Networking Sponsor

**Poster Reception**
5:30 PM - 7:00 PM | Exhibit Hall
Explore exciting products, services, and new research as you take another lap around the ePoster Hub and Exhibit Hall.

**Saturday, October 1**

**Nurse Networking Lunch**
12:00 PM - 1:00 PM | Exhibit Hall - HFSA Lounge
Calling all nursing professionals – this is the perfect place to share stories, voice your opinions on various topics, and network with your colleagues in an informal setting. Grab lunch in the Exhibit Hall and make your way back to the HFSA Lounge to eat and connect. We hope to see you there!

Sponsored by Platinum ASM Networking Sponsor

**Speed Mentoring**
Pre-Registration Required
4:30 PM - 5:30 PM | Potomac Terrace
This popular networking event functions like speed dating and allows mentees to shift from table to table and hold quick talks to connect with and ask questions of established mentors, based on their areas of interest of expertise.

**Sunday, October 2**

**HF Cardiovascular Team Reception**
12:15 PM - 1:15 PM | Exhibit Hall - HFSA Lounge
We welcome our nursing, pharmacy, and physician assistant attendees for an opportunity of exhilarating conversations. The Heart Failure Cardiovascular Team Reception is a great chance for you to reconnect with colleagues, make new connections, and unwind.

Sponsored by Platinum ASM Networking Sponsor

**President’s Reception**
7:00 PM - 8:00 PM | Cherry Blossom Ballroom
Grab a cocktail at this exciting meet and greet reception – the perfect opportunity for you to interact with HFSA leadership and other attendees.

Sponsored by Platinum ASM Networking Sponsor

**Journal of Cardiac Failure Reception**
8:00 PM - 9:00 PM | Lower Atrium
Join members of the Journal of Cardiac Failure to discuss all things heart failure. This is a great chance to interact with the editors and writers, as well as learn more about what the journal has to offer in a more informal setting.
Engage with Our 2022 Social Media Catalysts (SMCs)!

Our 2022 SMCs are the voice of #HFSA2022, providing real-time insights into the presentations delivered onsite and virtually – click each SMC’s Twitter handle below to stay connected!

- @LAuroraMD
- @waker0621
- @MarkBelkinMD
- @docbhardwaj
- @KellyofKansas
- @YevgeniyBR
- @spencercarter55
- @quin_denfeld
- @stormigale
- @EiranGorodeski
- @AHajduczok
- @ShahHashmani
- @drkaushikjain
- @AlexaB_KahnMD
- @rachkataria
- @eliekozaily1
- @SelmaFMohammed
- @noshreza
- @ShashankSinhaMD
- @Cards_pharm_gal

Social Media Catalysts

Engage with Our 2022 Social Media Catalysts (SMCs)!
Our 2022 SMCs are the voice of #HFSA2022, providing real-time insights into the presentations delivered onsite and virtually – click each SMC’s Twitter handle below to stay connected!

Onsite Attendees

Compete with onsite attendees and seek out the selfie/ussie spots throughout the meeting space! Find a frame, grab some friends and snap an ussie, then post it to Twitter and tag it with #HFSACHALLENGE22 and #HFSA2022. Every person in your ussie can tweet the photo and be entered for a chance to win - but they must tweet the photo on their own feed to qualify for an entry.

One (1) randomly selected attendee will be chosen per day to receive a $50 Amazon gift card. Tweet a new photo with a new frame daily for a chance to win on multiple days! One entry per attendee per day.

Virtual Attendees

Attendees registered for Virtual Only can also participate in the daily Twitter challenge! Simply tweet a photo that matches that day’s challenge, tag it with #HFSACHALLENGE22 and #HFSA2022, and you’ll be entered into daily drawings! One entry per attendee per day.

Friday, September 29: Get nostalgic with a throwback photo of a past HFSA meeting
Saturday, October 1: Snap a selfie in your home or office setup
Sunday, October 2: Tell us about your favorite presentation, speaker, poster or exhibitor
Monday, October 3: Tell us why you can’t wait for #HFSA2023! Who are you looking forward to seeing in person, what sessions are you most excited to see? #SeeYouIn23

One (1) randomly selected attendee will be chosen per day to receive a $50 Amazon gift card. Tweet daily for a chance to win multiple times! One entry per attendee per day.

No HFSA Annual Scientific Meeting sponsorship revenue is being utilized to fund prizes for attendee contests and raffles. All prizes are being funded solely by the HFSA.
Supporting Companies

Thank you to our Sponsors, Supporters and Partners!

Satellite Symposium (CEUs)
The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year’s Satellite Symposia.

American Regent, Inc.
AstraZeneca Pharmaceuticals
Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.
Bristol Myers Squibb
Cytokinetics Incorporated
Merck & Co., Inc.

Hands-on & Interactive Workshops (CEUs)
The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant and/or in-kind donations to support this year’s workshops.

Supported by unrestricted educational grants from:
Abbott
ABIOMED

Supported by in-kind educational donations from:
Abbott
ABIOMED
LivaNova
One Lambda, a part of Thermo Fisher Scientific, Inc.
Vyaire

Industry Expert Theaters (No CEUs)
ABIOMED
Alnylam Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.
Boston Scientific
Cytokinetics Incorporated
GETINGE
Impulse Dynamics
Pfizer, Inc.

Contemporary Forums (No CEUs)
Bristol Myers Squibb
CareDx, Inc.
CVRx
Cytokinetics Incorporated
Merck & Co., Inc.

Pre-Meeting Workshop (No CEUs)
ABIOMED
2022 Award Recipients

2022 Lifetime Achievement Award
The HFSA Lifetime Achievement Award is presented by the Executive Council of the HFSA to recognize a lifetime body of work by an individual who has made a significant and sustained contribution to the field of heart failure.

JoAnn Lindenfeld, MD, FHFS
Marilyn Prasun, RN, PhD, CCNS, CNL, CHFN

2022 HFSA Nursing Research Leadership Award
HFSA’s Nursing Research Leadership Award honors those with extraordinary achievement and excellence in nursing science that improves outcomes of patients with heart failure.

Debra Moser, PhD, RN

2022 HFSA Pioneer Award
The Pioneer Award is given to an innovator and pioneer in the field of heart failure. The Award notes the HFSA member's innovative role in heart failure which helps to set the stage for future generations of heart failure providers.

Kathleen Grady, PhD

2022 HFSA Distinguished Leadership Award
The Distinguished Leadership Award celebrates a leader in the field of heart failure in the areas of education and mentorship.

Eckhard Wolf, PhD

2022 HFSA Nursing Clinical Excellence Leadership Award
HFSA’s Nursing Clinical Excellence Leadership Award honors and supports clinical nursing excellence by a registered nurse who works directly with heart failure (HF) patients, their families, and other nurses providing HF services.

Maria Fe White, RN, MSN, FNP-ACNP-BC

2022 Distinguished HFSA Member Award
The Distinguished HFSA Member Award is intended to celebrate a member’s body of work in the field of heart failure and their work and service to the Heart Failure Society of America. The Award is intended for non-physician members of HFSA.

William Abraham, MD

2022 Outstanding Heart Failure Care Team Award
The Outstanding Heart Failure Care Team Award celebrates the accomplishments of a Heart Failure Care team, collectively.

VCU Pauley Heart Center Nurse-Led HF Disease Management Team

2022 Thomas L. Force Lecture
Selected by the ASM Program Chairs
Session: Excellence in Translational Science
Sunday, October 2 | 4:00 PM – 5:30PM | National Harbor 4/5

Clyde Yancy, MD, MSc

2022 HFSA Nursing Clinical Excellence Leadership Award
The Distinguished Leadership Award celebrates a leader in the field of heart failure in the areas of education and mentorship.

Eckhard Wolf, PhD

Nurse Investigator Award – Research and Clinical
Selected at the HFSA Annual Scientific Meeting 2022
Session: Sunday, October 2 | 9:45 AM – 10:45 AM | Potomac D
Announcement: Monday, October 3 | 11:00 AM | National Harbor 4/5

JNC New Investigator Award – Basic and Clinical
Selected at the HFSA Annual Scientific Meeting 2022
Session: Sunday, October 2 | 11:00 AM – 12:00 PM | Potomac D
Announcement: Monday, October 3 | 11:00 AM | National Harbor 4/5
Discover a new treatment option to manage NYHA Class II–III Obstructive HCM at BMS Booth 116

Learn more in a case-based discussion about a new approach to managing appropriate patients with symptomatic NYHA Class II–III obstructive HCM.

**Florian Rader, MD, MSc***
Co-Director, Clinic for Hypertrophic Cardiomyopathy
Medical Director, Hypertension Center of Excellence
Associate Director, Non-invasive Laboratory
Department of Cardiology, Smidt Heart Institute
Cedars-Sinai Medical Center

*Speaker is compensated by Bristol Myers Squibb.
HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association.

This Industry Contemporary Forum/Workshop is not part of the scientific program as planned by the HFSA Program Committee. This event is neither sponsored by nor endorsed by HFSA. This event does not qualify for continuing education credit.
### Schedule at a Glance

**Friday, September 30, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 2:00PM - 6:00PM | Building Your Cardiogenic Shock Team: Best Practices to Optimize Outcomes  
(Sponsored by ABIOMED) | National Harbor 10/11   |
| 6:00PM - 7:30PM | TEACH Workshop  
(Pre-Registration Required) | National Harbor 4/5     |
| 6:15PM - 7:15PM | Device Based Solutions for Optimal Heart Failure Patient Management  
(Sponsored by Boston Scientific) | Exhibit Hall (D/E) - IET1 |
| 6:15PM - 7:15PM | Recognizing the Underrecognized: Identification and Management of ATTR-CM Patients  
(Sponsored by Pfizer, Inc.) | Exhibit Hall (D/E) - IET2 |
| 6:45AM - 7:45AM | The Trajectory of Worsening Heart Failure and Considerations for Outcomes and Cost of Care  
(Sponsored by Cytokinetics Incorporated) | Potomac C               |
| 8:00AM - 8:30AM | Professionals in Training Lounge Session: Roundtable Discussion: Careers in Technology/Industry | Chesapeake 2           |
| 8:30AM - 9:00AM | Professionals in Training Lounge Session: Roundtable Discussion: Building a Private Practice/Establishing a Referral Base | Chesapeake 2           |
| 9:30AM - 11:30AM | Presidential Plenary Session  
- Opening Remarks: President’s Address and Award Announcements  
- Opening Keynote Address: The Importance of Innovation in Heart Failure: Perspectives on Scientific, Regulatory, and Funding Initiatives  
(Presented by Michael Bristow, MD, PhD (University of Colorado) and Gary Gibbons, MD (National Heart, Lung and Blood Institute) / Featuring Panelists Bram Zuckerman, MD (FDA) and Mona Fiuzat, PharmD, FHFS (FDA)) | Potomac A/B             |

### Saturday, October 1, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 8:00AM - 9:15AM | Management of HFrEF: Will Novel Therapies Fit into Existing Treatment Paradigms?  
(Supported through an unrestricted educational grant by Merck & Co., Inc.) | National Harbor 2/3     |
| 9:30AM - 11:30AM | A Case-based Discussion on a New Approach to Managing Select Patients with Symptomatic NYHA Class II-III Obstructive HCM  
(Sponsored by Bristol Myers Squibb) | National Harbor 4/5     |

Looking for detailed CE information? View the CE Book [here](#)!
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35AM - 12:35PM</td>
<td>Professionals in Training Lounge Session: Leadership Session with Dr. Lawanda Wesley</td>
<td>Chesapeake 2</td>
</tr>
<tr>
<td></td>
<td><em>The Role and Intersections of Structural Racism &amp; Sanctioned Oppression: A Call to Action to Move Towards Anti-racist Clinical Care and Approaches (Limited Capacity)</em></td>
<td></td>
</tr>
<tr>
<td>11:35AM - 1:35PM</td>
<td>Lunch</td>
<td>Exhibit Hall (D/E)</td>
</tr>
<tr>
<td>12:00PM - 1:00PM</td>
<td>ePoster Viewing Session II</td>
<td>Exhibit Hall (D/E) - ePoster Hub</td>
</tr>
<tr>
<td>12:00PM - 1:00PM</td>
<td>Oral Poster Session II</td>
<td>Exhibit Hall (D/E)</td>
</tr>
<tr>
<td>12:15PM - 1:15PM</td>
<td>Nurse Networking Lunch</td>
<td>Exhibit Hall (D/E) - NOVARTIS</td>
</tr>
<tr>
<td>12:15PM - 1:15PM</td>
<td>Hope is Here – A Modern Approach to Heart Failure Treatment</td>
<td>Exhibit Hall (D/E) - IET1</td>
</tr>
<tr>
<td>12:30PM - 1:30PM</td>
<td>HFSA AHFTC Board Certification Review 2022 Faculty Office Hours</td>
<td>Magnolia 1</td>
</tr>
<tr>
<td>1:45PM - 2:45PM</td>
<td>FDA Special Session: Background Medical Therapy for HF Clinical Trials</td>
<td>Potomac C</td>
</tr>
<tr>
<td>1:45PM - 2:45PM</td>
<td>#ConstructivelyDisruptive at JCF</td>
<td>Potomac D</td>
</tr>
<tr>
<td>1:45PM - 3:00PM</td>
<td>Dangerous Liaisons - Cardio-Oncology</td>
<td>National Harbor 10/11</td>
</tr>
<tr>
<td>1:45PM - 3:00PM</td>
<td>Many Roads Lead to Rome: Evolving Training Pathways for the Advanced Heart Failure and Critical Care Cardiologist</td>
<td>National Harbor 4/5</td>
</tr>
<tr>
<td>1:45PM - 3:00PM</td>
<td>Medical Therapy of Heart Failure with Reduced Ejection Fraction: New Guidelines and Evolving Clinical Practice</td>
<td>National Harbor 2/3</td>
</tr>
<tr>
<td>1:45PM - 3:15PM</td>
<td>Hands-On Workshop: Cardiogenic Shock (Limited Capacity)</td>
<td>Potomac 4/5</td>
</tr>
<tr>
<td>3:15PM - 4:15PM</td>
<td>Women in Heart Failure: What are the Opportunities?</td>
<td>Potomac C</td>
</tr>
<tr>
<td>3:15PM - 4:15PM</td>
<td>Hypertrophic Cardiomyopathy: It’s a New Dawn…And I’m Feeling Good</td>
<td>National Harbor 2/3</td>
</tr>
<tr>
<td>3:15PM - 4:15PM</td>
<td>New Device Based Therapies for Severe HF: Shunts etc.</td>
<td>National Harbor 10/11</td>
</tr>
<tr>
<td>3:15PM - 4:15PM</td>
<td>Nutrition and Obesity Management in Heart Failure</td>
<td>National Harbor 4/5</td>
</tr>
<tr>
<td>4:30PM - 5:30PM</td>
<td>Speed Mentoring</td>
<td>Potomac Terrace</td>
</tr>
<tr>
<td>5:30PM - 6:15PM</td>
<td>Tweet Up</td>
<td>Exhibit Hall (D/E) - HFSA Lounge</td>
</tr>
<tr>
<td>5:30PM - 6:30PM</td>
<td>Women in HF Reception</td>
<td>Potomac C</td>
</tr>
<tr>
<td>5:30PM - 6:30PM</td>
<td><em>Featuring Dr. Yvonne Cagle</em></td>
<td></td>
</tr>
<tr>
<td>5:30PM - 6:30PM</td>
<td><em>Sponsored by Platinum ASM Networking Sponsor NOVARTIS</em></td>
<td></td>
</tr>
<tr>
<td>5:30PM - 7:00PM</td>
<td>Poster Reception</td>
<td>Exhibit Hall (D/E)</td>
</tr>
</tbody>
</table>

**Schedule at a Glance**

**KEY:**
- CEUs
- Contemporary Forum
- Industry Expert Theater
- Networking
- Satellite Symposia
- Scientific Session
- Workshop
- Posters
- Livestream
- OnDemand
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients with Hypertrophic Cardiomyopathy
Supported through an unrestricted educational grant by Bristol Myers Squibb

Baroreflex Activation Therapy: A Novel Approach for HFrEF Patients
Sponsored by CVRx

Our Hearts Will Go On - What We Learned from COVID-19 and How We Move Forward
National Harbor 4/5

Heart Transplant Allocation in 2022
National Harbor 2/3

Let's Talk About Sex (Differences in Heart Failure)
National Harbor 4/5

New Concepts and Controversies in Pulmonary Hypertension and Right Ventricular Failure
Potomac C

Professionals in Training Lounge Session: Leadership Session with Dr. David Newsome - Distinguished Toastmaster
Off-the-Cuff: Mastering Extemporaneous Speaking (Limited Capacity)
Chesapeake 2
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00PM - 2:00PM</td>
<td>Lunch</td>
<td>Exhibit Hall (D/E)</td>
</tr>
</tbody>
</table>
| 12:15PM - 1:15PM | HF Cardiovascular Team Reception  
Sponsored by Platinum ASM Networking Sponsor Novartis | Exhibit Hall (D/E) - HFSA Lounge |
| 12:30PM - 1:30PM | ePoster Viewing Session IV  
Oral Poster Session IV  
Tackling Disparities in Cardiogenic Shock  
Sponsored by GETINGE  
Jardiance® (empagliflozin) tablets: A Review of the Latest Data  
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC | Exhibit Hall (D/E) - ePoster Hub, Exhibit Hall (D/E) - IET1 |
| 1:00PM - 1:30PM | Professionals in Training Lounge Session: Roundtable Discussion: Careers in the VA and FDA | Chesapeake 2 |
| 1:30PM - 2:10PM | Professionals in Training Lounge Session: Meet the Editors of Heart Failure Journals  
(JCF, JACC HF, Circ HF) | Chesapeake 2 |
| 2:15PM - 3:15PM | Multidisciplinary Heart Failure Clinics                                                     | Potomac D |
| 2:15PM - 3:45PM | Global Innovations in the Care of Patients with Heart Failure  
Mihai Gheorghita Lecture  
Leveraging Genetics for Heart Failure Therapy: Where Are We Headed?  
Controversies in HFpEF  
Referral for Advanced HF Care  
Hands-On Workshop: How to Manage and Monitor Patients with VADs: Alarms and PA Pressure Monitors  
| 2:30PM - 3:00PM | Professionals in Training Lounge Session: Interview with Dr. Amit Goyal, Co-founder of CardioNerds Podcast | Chesapeake 2 |
| 4:00PM - 5:15PM | “Oh the Places We’ll Need to Go”: Unmet Needs and Debates in Cardiogenic Shock  
Inherited Dilated Cardiomyopathies: Can We Rewrite the Stars?  
Implications of Comorbidities Across the HF Continuum  
A Case-based Approach to Diagnosis and Management of Cardiac Amyloidosis | National Harbor 2/3, Potomac D, National Harbor 10/11 |
| 4:00PM - 5:30PM | Excellence in Translational Science  
Thomas L. Force Lecture | Potomac C |
| 5:30PM - 7:00PM | New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data  
Supported through an unrestricted educational grant by Cytokinetics Incorporated  
Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management  
Supported through an unrestricted educational grant by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC  
The Future of Post-Cardiac Transplant Care: Strategies to Predict and Improve Outcomes  
Sponsored by CareDx, Inc. | National Harbor 2/3, National Harbor 10/11, National Harbor 4/5 |
## Schedule at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00PM - 8:00PM</td>
<td>President’s Reception</td>
<td>Cherry Blossom Ballroom</td>
</tr>
<tr>
<td>8:00PM - 9:00PM</td>
<td><strong>Journal of Cardiac Failure Reception</strong></td>
<td>Lower Atrium</td>
</tr>
</tbody>
</table>

### Monday, October 3, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45AM - 7:45AM</td>
<td>Treatment Considerations for Patients with HFrEF and Select Updates From the 2022 HF Guideline</td>
<td>National Harbor 4/5</td>
</tr>
<tr>
<td>7:00AM - 7:45AM</td>
<td><strong>Special DELIVERy: Emerging Insights Related to the DELIVER Trial</strong></td>
<td>National Harbor 2/3</td>
</tr>
<tr>
<td>8:00AM - 9:30AM</td>
<td>Monday Plenary Session: Cardiac Xenotransplantation: Where We Are and Where We Are Going Featuring University of Maryland Heart Xenotransplant Team</td>
<td>Potomac A/B</td>
</tr>
<tr>
<td>9:45AM - 10:45AM</td>
<td>Heart Failure Research Update: Conducting HF Trials in the U.S.</td>
<td>Potomac C</td>
</tr>
<tr>
<td></td>
<td>Debating Volume-based Versus Methods and Devices to Measure Congestion in Heart Failure</td>
<td>National Harbor 4/5</td>
</tr>
<tr>
<td>9:45AM - 11:00AM</td>
<td><strong>Signed, Sealed, and DELIVERed</strong></td>
<td>National Harbor 2/3</td>
</tr>
<tr>
<td></td>
<td>Hands-On Workshop: Monitoring of Heart Transplant Rejection (Limited Capacity)</td>
<td>Potomac 4/5</td>
</tr>
<tr>
<td>11:00AM - 12:00PM</td>
<td>The Great Debates</td>
<td>National Harbor 4/5</td>
</tr>
<tr>
<td></td>
<td>Clinical Conundrums</td>
<td>Potomac D</td>
</tr>
<tr>
<td></td>
<td>The Evolving Care of Patients with Durable LVADs in Advanced HF Care</td>
<td>Potomac C</td>
</tr>
<tr>
<td></td>
<td>Health Equity in Heart Failure: Provider and Patient Perspectives</td>
<td>National Harbor 10/11</td>
</tr>
</tbody>
</table>

Looking for detailed CE information? View the CE Book [here](#)!
Satellite symposia provide opportunities to learn about new and emerging clinical options not addressed in the scientific program. While not part of the official scientific program, these industry-supported symposia are an important part of the ASM as they are planned to meet the same standards of evidence, scientific rigor, and fair balance as scientific sessions.

**Friday, September 30**

**Management of HFrEF: Will Novel Therapies Fit into Existing Treatment Paradigms?**
7:30 PM – 9:00 PM | National Harbor 2/3

**Chair:** Ileana Piña, MD, MPH  
Biykem Bozkurt, MD, PhD  
Javed Butler, MD, MPH

*Supported by an unrestricted educational grant from Merck & Co., Inc.*

**Saturday, October 1, 2022**

**Bridging the Gap Between Evidence and Clinical Practice: Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure**
8:00 AM - 9:15 AM | National Harbor 2/3

**Chair:** Javed Butler, MD, MPH  
Scott Solomon, MD  
Mikhail Kosiborod, MD  
Alanna Morris, MD, MSc

*Supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals*

**Fine-Tuning the Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction**
7:00 PM - 8:30 PM | National Harbor 2/3

**Chair:** John Teerlink, MD  
G. Michael Felker, MD, MHS  
Robert Mentz, MD  
Alanna Morris, MD, MSc

*Supported by an unrestricted independent educational grant from Cytokinetics Incorporated*

**Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF**
7:00 PM - 8:30 PM | National Harbor 10/11

**Chair:** Javed Butler, MD, MPH  
Stefan Anker, MD, PhD  
Biykem Bozkurt, MD, PhD  
Muthiah Vaduganathan, MD, MPH

*Supported by an unrestricted educational grant from American Regent, Inc.*

**Sunday, October 2, 2022**

**Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?**
6:45 AM - 7:45 AM | National Harbor 2/3

**Chair:** Milind Desai, MD, MBA  
Neal Lakdawala, MD  
Anjali Owens, MD

*Supported by an unrestricted independent educational grant from Bristol Myers Squibb*

**New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data**
5:30 PM - 7:00 PM | National Harbor 2/3

**Chair:** Theodore Abraham, MD  
Anjali Owens, MD  
Sara Saberi, MD

*Supported by an unrestricted educational grant from Cytokinetics Incorporated*

**Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management**
5:30 PM - 7:00 PM | National Harbor 10/11

**Chair:** Andrew Sauer, MD  
Justin Ezekowitz, MD  
Aferdita Spahillari, MD  
Ashley Tringale, CNP

*Supported by an unrestricted educational grant from Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC*
Industry Expert Theaters are non-CEU educational activities that allow industry experts to provide clinical updates and educate attendees on current therapies, disease states, products, and pipeline activities. Sessions are formatted for learning and are a great way to receive higher level interaction and engagement with company representatives.

**Educational activities held in the exhibit hall do not provide continuing education credit.**

**Friday, September 30, 2022**

**Device Based Solutions for Optimal Heart Failure Patient Management**

6:15 PM – 7:15 PM | Industry Expert Theater 1, Exhibit Hall

**Faculty:** Jag Singh, MD, PhD / John Boehmer, MD

**Moderator:** JoAnn Lindenfeld, MD

**Description:** The intersection between heart failure (HF) and electrophysiology (EP) in the management of HF patients is well established and highlighted in the recent AHA/ACC/HFSA HF Guideline update. Opportunities exist for better collaboration to maximize patient care utilizing device feature capabilities including predictive diagnostics and direct treatment options. In this session we will discuss how best to integrate HF/EP management to optimize Cardiac Resynchronization Therapy (CRT), solutions for chronotropic incompetence, and how HeartLogic™ can identify early opportunities for intervention to preempt HF decompensation while additionally providing valuable insight into both device and arrhythmia management.

**Learning Objectives:**

- Discuss intersection between HF and EP related to device-based care of HF patients
- Explain importance of CRT therapy and device-based solutions to manage HF patients
- Review HeartLogic implementation and clinical data including physiologic insights into rhythm and device-based HF patient management

*Sponsored by Boston Scientific*

**Recognizing the Underrecognized: Identification and Management of ATTR-CM Patients**

6:15 PM – 7:15 PM | Industry Expert Theater 2, Exhibit Hall

**Faculty:** Catherine Marti, MD, MSc / Dermot Phelan, MD, PhD, FASE, FACC

**Description:** Transthyretin amyloid cardiomyopathy (or ATTR-CM) is an underrecognized and underdiagnosed progressive disease that presents as heart failure. This presentation will provide an overview of ATTR-CM, highlighting how to recognize the signs and symptoms that raise suspicion of ATTR-CM, while introducing approaches to achieve an appropriate diagnosis. The program will end with a review of the clinical data for a treatment option for ATTR-CM.

*Sponsored by Pfizer, Inc.*

**Saturday, October 1, 2022**

**Hope is Here – A Modern Approach to Heart Failure Treatment**

12:15 PM – 1:15 PM | Industry Expert Theater 1, Exhibit Hall

**Faculty:** Anu Lala, MD / William Abraham, MD / Javed Butler, MD / Andrew Sauer, MD

**Description:** The importance of accurately assessing the NYHA classification of patients with heart
failure has never been higher! For almost two decades, the only device available to treat heart failure has been cardiac resynchronization (CRT) devices. But now, everything has changed for patients remaining symptomatic despite being on guideline-directed medical treatment (GDMT) — available device options exist.

This session will examine cardiac contractility modulation therapy, how it works, and what can be expected regarding treatment outcomes for NYHA Class III patients remaining symptomatic despite guideline-directed medical therapy. The faculty panel will discuss the MoA of CCM therapy, provide an overview of historical and ongoing clinical trials, and share their experiences in identifying appropriate candidates for this device therapy with few or no other options.

In conclusion, this panel will share their patient experiences concerning the dilemma of quality of life versus quantity of life and how they feel about the research explicitly conducted for this heart failure population.

Learning Objectives:
• Examine the growing population of patients with heart failure remaining symptomatic despite being on GDMT
• Explain the indications for cardiac contractility modulation for the management of heart failure
• Describe the mechanism of action of cardiac contractility modulation and its effects on calcium cycling and genetic expression
• Review the clinical experience with CCM therapy and ongoing clinical research
• Acquire best practices for screening heart failure patients who remain symptomatic regardless of GDMT
• Learn about the quality-of-life issues that affect heart failure patients

Sponsored by Impulse Dynamics

Ongoing Burden of Symptomatic Chronic HFrEF
Recognizing Early Signs or Symptoms of Worsening Trajectory
12:15 PM – 1:15 PM | Industry Expert Theater 2, Exhibit Hall
Faculty: Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN / Robert Mentz, MD, FHFSA, FACC, FAHA / Muthiah Vaduganathan, MD, MPH, FACC

Description: During this presentation we will address the ongoing healthcare burden of patients with symptomatic chronic HFrEF. We will also discuss and highlight the challenges of worsening signs or symptoms in high-risk patients, including those with hypotension and low EF.

Experts will review clinical approaches that may help in recognizing early signs or symptoms of patients in the worsening HFrEF trajectory.

Learning Objectives:
• Discuss the ongoing healthcare burden of patients with symptomatic chronic HFrEF
• Understand the challenges with worsening signs or symptoms in select high-risk patients
• Review clinical approaches to recognize early signs or symptoms of worsening HFrEF trajectory

Sponsored by Cytokinetics Incorporated
A New Treatment Option: Discover AMVUTTRA™ (vutrisiran)
5:45 PM – 6:45 PM | Industry Expert Theater 1, Exhibit Hall
Faculty: Amanda Peltier, MD, MS / Brett Sperry, MD

Description: Join our distinguished faculty as they discuss recognizing, diagnosing, and managing polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. They will provide an overview of hATTR amyloidosis and review the clinical profile of AMVUTTRA, a new treatment for the polyneuropathy of hATTR amyloidosis in adults.

AMVUTTRA has warnings and precautions for reduced serum vitamin A levels and recommended supplementation. The most common adverse reactions are arthralgia, dyspnea, and vitamin A decreased. For additional information about AMVUTTRA, please see the Important Safety Information and full Prescribing Information.

Learning Objectives:
• Provide a disease overview of hATTR amyloidosis
• Discuss a hypothetical patient case, including symptom presentation and management goals
• Review the clinical efficacy and safety of AMVUTTRA™ (vutrisiran) as a treatment option for the polyneuropathy of hATTR amyloidosis in adults
• Provide an overview of Alnylam AssistTM, a patient support program for adults who have been prescribed AMVUTTRA for the polyneuropathy of hATTR amyloidosis

Sponsored by Alnylam Pharmaceuticals, Inc.

Turning the Tide of Heart Failure: Who Will Rise to the Challenge?
5:45 PM – 6:45 PM | Industry Expert Theater 2, Exhibit Hall
Faculty: Bobbi Bogaev-Chapman, MD / Navin Kapur, MD / Jeff Moses, MD / Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHfSA, FAAN

Description: This presentation sponsored by ABIOMED, will discuss underutilized treatment opportunities for heart failure patients, current trials and published data that support these interventions.

Learning Objectives:
• Acknowledge the gap in CAD assessment for HF patients and the opportunity to identify ischemia as the driver for worsening HF
• Recognize the importance of complete revascularization as a key treatment modality in the HFrEF patient
• Initiate standardized testing for coronary artery disease to assure more timely and appropriate treatment

Sponsored by ABIOMED
Industry Expert Theaters (No CEUs)

Sunday, October 2, 2022

**Tackling Disparities in Cardiogenic Shock**
12:30 PM – 1:30 PM | Industry Expert Theater 1, Exhibit Hall  
**Faculty:** Ersilia DeFilippis, MD, FACC / Albert J. Hicks, III, MD, MPH / Jerry D. Estep, MD, FACC, FASE  
**Moderator:** Mariell Jessup, MD, MSc  

**Description:** There are recognized disparities in the care of patients with CVD. This session will focus on assessing biological and socioeconomic determinants of cardiogenic shock risk in vulnerable or overlooked populations with CVD. Strategies to reduce identified inequalities in care delivery, advanced treatment options to diminish adverse outcome rates in these patients will be discussed.  

*Sponsored by GETINGE*

**Jardiance® (empagliflozin) tablets: A Review of the Latest Data**
12:30 PM – 1:30 PM | Industry Expert Theater 2, Exhibit Hall  
**Faculty:** Jonathan D. Rich, MD, FACC, FHFA  

**Description:** This program will review recent clinical trial data for JARDIANE. It will also provide information on JARDIANE initiation and dosing, as well as guidance for monitoring patients on JARDIANE. Attendees will have the opportunity to ask the faculty questions about the data presented.  

*Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC*
Contemporary Forums are industry-supported sessions offering attendees clinical updates and education on current therapies, disease states, products and pipeline activities.

**Friday, September 30, 2022**

**Pre-Meeting Workshop!**

**Building Your Cardiogenic Shock Team: Best Practices to Optimize Outcomes**
2:00 PM – 6:00 PM | National Harbor 10/11
**Faculty:** Jacob Abraham, MD / Rohan Goswami, MD / Manreet Kanwar, MD / Navin Kapur, MD

**Description:** This program sponsored by ABIOMED, will bring together key opinion leaders to discuss best practices related to the management of patients in cardiogenic shock and the structure of the teams who take care of this patient population.

**Learning Objectives:**
- Identify the role of device selection and escalation to optimize outcomes in cardiogenic shock
- Distinguish between the phenotypic differences of AMI CS and heart failure shock and the variable treatment strategies
- Understand best practices to build a cardiogenic shock team

*Sponsored by ABIOMED*

**A Case-based Discussion on a New Approach to Managing Select Patients with Symptomatic NYHA Class II-III Obstructive HCM**
7:30 PM – 9:00 PM | National Harbor 4/5
**Faculty:** Florian Rader, MD, MSc

**Description:** Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) is a chronic, progressive myocardial disease associated with potential complications including arrhythmias, stroke, heart failure, and sudden cardiac death. This session will review clinical data on a new treatment option for select patients with symptomatic NYHA class II-III obstructive HCM and use a hypothetical case-based format to discuss a potential management strategy for these patients.

**Learning Objectives:**
- Understand the clinical data on a new oral treatment option for select patients with symptomatic NYHA class II-III obstructive HCM
- Describe the appropriate patients for treatment, the initiation process, and the monitoring required for a novel symptomatic NYHA class II-III obstructive HCM treatment option, through a hypothetical case-based example

*Sponsored by Bristol Myers Squibb*

**Saturday, October 1, 2022**

**The Trajectory of Worsening Heart Failure and Considerations for Outcomes and Cost of Care**
6:45 AM – 7:45 AM | Potomac C
**Faculty:** Nihar Desai, MD, MPH / Stephen Greene, MD / Alanna Morris, MD, MSc / Anuradha Lala-Trindade, MD
Learning Objectives:
In patients with symptomatic HFrEF with worsening signs and symptoms:
• Understand the trajectory, natural history, and prognosis of patients with symptomatic HFrEF and worsening signs and symptoms
• Explore the clinical and economic impact of not achieving optimization of evidence-based therapies in this patient population
• Describe the impact and gaps for underserved patient populations where GDMT is challenging and infrequently achieved
• Discuss challenges from health economics and policy perspectives to help mitigate residual risk in this HF population with high unmet need

Sponsored by Cytokinetics Incorporated

Sunday, October 2, 2022
Baroreflex Activation Therapy: A Novel Approach for HFrEF Patients
6:45 AM – 7:45 AM | National Harbor 4/5
Faculty: Marat Fudim, MD / Robert Cole, MD / Luanda Grazette, MD

Description: Educational symposium and panel discussion on the physiologic rationale for baroreflex activation, clinical data, and appropriate patient selection for Barostim Therapy in HFrEF patients.

Learning Objectives:
• Unmet needs and limits of GDMT
• Current device options to improve HF symptoms beyond GDMT
• Role of the autonomic nervous system in heart failure
• Central role of the baroreflex in autonomic and cardiovascular regulation
• Impact of down-regulation of the baroreflex in HFrEF patients
• Barostim Clinical Data and Therapy Overview
• Barostim Patient Case Studies and Real-World Experience

Sponsored by CVRx

The Future of Post-Cardiac Transplant Care: Strategies to Predict and Improve Outcomes
5:30 PM – 7:00 PM | National Harbor 4/5
Faculty: Jeremy Kobulnik, MD / Amit Alam, MD / Shelley Hall, MD / Jon Kobashigawa, MD

Description: Learn about newest technologies and clinical studies in post heart transplant surveillance space that will include:
• A non-invasive method of monitoring graft and recipient health through HeartCare
• Molecular Signals in Blood and Tissue, and the their clinical implications and performance in a real-world cohort.
• A New Artificial Intelligence prognostic tool for Cardiac Allograft Vasculopathy

Sponsored by CareDx, Inc.
Monday, October 3, 2022
Treatment Considerations for Patients with HFrEF and Select Updates From the 2022 HF Guideline
6:45 AM – 7:45 AM | National Harbor 4/5
Faculty: Javed Butler, MD

Learning Objectives:
• Highlight the impact of HFrEF in the United States
• Review a treatment option for reducing the risk of HFH and CV death in patients with HFrEF
• Provide an overview of selected updates to the 2022 AHA/ACC/HFSA Guideline for the management of HF

Sponsored by Merck & Co., Inc.
Clinical Trial Central

CTR-001

Safety, Efficacy, And Quantitative Understanding Of Obstruction, Impact Of Aficamten In Hypertrophic Cardiomyopathy (SEQUOIA-HCM) Study Design: A Phase 3 Study

Acronym: SEQUOIA-HCM
Sponsor: Cytokinetics Incorporated
Supporter: Cytokinetics Incorporated

Description: Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM (SEQUOIA-HCM), is a Phase 3 multi-center, randomized, double-blind, placebo-controlled clinical trial exploring the efficacy of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This study will evaluate the effect of treatment with aficamten compared with placebo on exercise capacity, measured by change in peak oxygen uptake (pVO2) on cardiopulmonary exercise testing (CPET), from baseline to Week 24. Secondary endpoints will evaluate the treatment effect of aficamten on Kansas City Cardiomyopathy Questionnaire (KCCQ), New York Heart Association (NYHA) functional class, and hemodynamics.

CTR-002

Ultrafiltration Versus IV Diuretics In Worsening Heart Failure (REVERSE-HF)

Acronym: REVERSE-HF
Sponsor: Nuwellis, Inc.
Supporter: Nuwellis, Inc.

Description: The Ultrafiltration versus IV Diuretics in Worsening Heart Failure (REVERSE-HF) trial is a prospective, multicenter, randomized controlled trial to evaluate the clinical benefit and economic value of adjustable ultrafiltration (AUF) versus adjustable loop diuretics (ALD) in patients (n=372) with an acute exacerbation of chronic heart failure (HF) and congestive physiology. The primary composite endpoint will be analyzed via the hierarchical win ratio (WR) statistical method, consisting of all-cause mortality within 90 days, HF events (defined as any HF rehospitalization or unplanned use of IV loop diuretics, vasoactive medications or Aquadex therapy in any outpatient setting) within 30 days, and time to first HF events within 90 days. The economic value of AUF will be derived from procedure information, resource utilization (e.g., hospital readmissions, length of hospital stay, ED/ER visits), mortality, and/or quality of life (KCCQ). Patients will be followed for 6 months post-treatment discharge to assess HF and CV events, quality of life, mortality, days alive outside of the hospital, cardiac and renal function variables, fluid balance and weight loss.

CTR-003

Continuous Remote Patient Monitoring In Patients With Heart Failure (CASCADE Study): Mixed Methods Feasibility Study

Acronym: CASCADE
Sponsor: NorthShore University Health System
Supporter: physIQ, Inc.

Description: The primary aim of this study is to determine the feasibility and preliminary efficacy of a cRPM solution in patients with HF at NorthShore University HealthSystem.

Background: Heart failure (HF) is a prevalent chronic disease and is associated with increases in mortality and morbidity. HF is a leading cause of hospitalizations and readmissions in the United States. A potentially promising area for preventing HF readmissions is continuous remote patient monitoring (cRPM).

Methods: This study is a feasibility study and uses physIQ’s pinpointQTM solution. PinpointQTM includes a wearable biosensor that streams physiologic data to the cloud where artificial analytics are applied and notifications are generated to the clinical team. We will continuously monitor patients with HF for 30 days after discharge. Eligible patients admitted with an HF exacerbation at NorthShore University HealthSystem are being recruited, and the wearable biosensor is placed before discharge. The biosensor collects physiological ambulatory data, which are analyzed for signs of patient deterioration. Participants are also completing a daily survey through a dedicated study smartphone. If prespecified criteria from the physiological data and survey results are met, a notification is triggered, and a predetermined electronic health record-based pathway of telephonic management is completed. This is phase 3 of the this study1 where we will be enrolling 45 patients for phase 3. The combined results of phases 1, 2, and 3 will be analyzed to determine the feasibility of a CRPM program in patients with HF2.
Semi-structured interviews are being conducted with key stakeholders, including patients, and these results will be analyzed using the affective adaptation of the technology acceptance model.

**Results & Conclusions:** A cRPM program may offer a low-risk solution to improve care of patients with HF after hospital discharge and may help to decrease readmission of patients with HF to the hospital. This protocol may also lay the groundwork for the use of cRPM solutions in other groups of patients considered to be at high risk.


**CTR-004**

**ALLAY-HF: Safety And Efficacy Of The Alleviant System For No-implant Interatrial Shunt Creation In Patients With Chronic Heart Failure**

**Acronym:** ALLAY-HF  
**Sponsor:** Alleviant Medical  
**Supporter:** Alleviant Medical

**Description:** ALLAY-HF aims to evaluate the safety and efficacy of a minimally invasive no-implant interatrial shunt (Alleviant Medical, Inc.) in chronic heart failure. The trial is a prospective, randomized, adaptive, sham-controlled, double-blinded study in patients with heart failure with mildly-reduced or preserved ejection fraction (HFmrEF/HFpEF) with abnormal exercise hemodynamics at baseline. Patients will be randomized 1:1 between the investigational device procedure and sham-control procedure. The trial will enroll 400-700 patients at 75+ sites worldwide. The primary outcome measure will be a hierarchical analysis of cardiovascular mortality, heart failure hospitalization and worsening events, and quality of life at 12-month follow-up.

**CTR-005**

**GenePHIT, A Phase 2 Trial Of Nan-101, A Novel Gene Therapy For Congestive Heart Failure**

**Acronym:** GenePHIT  
**Sponsor:** Asklepios BioPharmaceutical, Inc.  
**Supporter:** Cadent Medical Communications, LLC, a Syneos Health® group company

**Description:** The Gene Phosphatase Inhibition Therapy trial, or GenePHIT, is a phase 2, adaptive, double-blind, placebo-controlled, randomized, multicenter trial designed to evaluate the efficacy, safety, and tolerability of a single intracoronary infusion of NAN-101. This investigational adeno-associated virus (AAV) gene therapy is designed to stimulate protein phosphatase constitutively active inhibitor 1 (I-1c) to block the action of PP1 and ultimately lead to restoration of Ca2+ cycling in cardiac myocytes. The GenePHIT trial will include adults with chronic nonischemic cardiomyopathy, a left ventricular ejection fraction (LVEF) between 15% - 35%, a 6-minute walk test (6MWT) distance of >50 meters, and Class III heart failure that has been medically stable for ≥4 weeks while on guidelines-based medical therapy. Following screening, patients will be randomized to receive low-dose NAN-101, high-dose NAN-101, or placebo. GenePHIT will continue for 52 weeks, at which point outcomes will be assessed. The primary efficacy endpoint will use a modified win ratio defined by a hierarchical evaluation of the following assessments as shown in this order: cardiovascular-related death; functional class; LVEF change from baseline; peak exercise VO2 change from baseline; and 6MWT change from baseline. Secondary efficacy endpoints, including functional status, hospitalizations, echocardiographic assessments, NT-proBNP levels, and quality of life measures will be assessed, as well as safety endpoints.

**CTR-006**

**Enrolling Patients In Cardiac Amyloid Reaching For Extended Survival (REFERENCES) Trials: Two Placebo-controlled, Double-blind, Randomized, International Phase 3 Trials Assessing CAEL-101 In Patients With Mayo Stage IIia Or Stage IIib AL Amyloidosis**

**Acronym:** CARES  
**Sponsor:** Alexion, AstraZeneca Rare Disease  
**Supporter:** Alexion, AstraZeneca Rare Disease

**Description:** CAEL-101, a monoclonal antibody, binds to amyloid fibrils and may facilitate their removal and improve organ function and patient survival. Our objective was to evaluate the efficacy and safety of CAEL-101 when administered concurrently with SoC anti-PCD therapy in treatment-naïve patients with cardiac AL amyloidosis in Mayo Stages IIia (NCT04504825; 301) and IIib (NCT04512235; 302).

**Introduction:** Light-chain (AL) amyloidosis is a rare,
Clinical Trial Central

progressive, systemic disorder caused by plasma cell dyscrasia (PCD). Amyloid fibrils deposit in organs causing progressive damage and death. The disease is staged at diagnosis based on cardiac biomarkers using the European Modification of the Mayo 2004 staging system. Median survival for patients in Mayo Stages IIIb and IIIa is 4 and 24 months, respectively. The standard of care (SoC) is anti-PCD therapy to suppress amyloid fibril generation. As yet, there are no therapies that remove deposited fibrils.

**Methods:** These international, multicenter, double-blind, randomized, phase 3 trials are enrolling patients at >100 sites in >20 countries. Newly diagnosed adults with Stage IIIb or IIIa AL cardiac amyloidosis, measurable hematologic disease, and histopathologic diagnosis of AL amyloidosis with planned first-line treatment with cyclophosphamide-bortezomib-dexamethasone-based therapy with/without daratumumab administered as SoC are eligible. Patients with other forms of amyloidosis, symptomatic orthostatic hypotension, or concurrent multiple myeloma are ineligible. Patients in Mayo Stages IIIb (N = 124) and IIIa (N = 267) are being randomized 2:1 to receive once-weekly IV infusions of CAEL-101 (1000 mg/m2) or placebo for 4 weeks, followed by maintenance dosing every 2 weeks in these survival-driven studies (Figure). Overall survival (primary endpoint) will be analyzed via time-to-event log-rank statistics. Secondary endpoints include quality of life (QoL) measured as Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS), cardiac improvement measured as % Global Longitudinal Strain (%GLS), functional improvement assessment measured as 6-minute walk test (6MWT), and safety evaluations.

**Results:** As of July 21, 2022, there were 53 patients enrolled in 301 and 128 patients in 302.

**Discussion:** These ongoing trials will evaluate CAEL-101 efficacy and safety as potential first-in-class treatment to reduce amyloid deposits in patients with cardiac AL amyloidosis. Notably, 301 (Mayo Stage IIIb) is the first randomized, placebo-controlled efficacy clinical trial to formally assess the effects of a pharmacologic agent in this severely ill population. These trials are ongoing. AL amyloidosis is a rare disease that presents with nonspecific symptoms making it difficult to diagnose and treat. There continues to be a critical unmet need to remove deposited amyloid fibril and improve patient survival and QoL.
Emerging Therapies Row is an exciting opportunity at this year’s HFSA meeting. HFSA provides a unique forum for companies early in development of diagnostics and therapies to the heart failure space to share information about their emerging products. Located in a designated focus area in the Exhibit Hall, each participating company will have a tabletop exhibit area to present their diagnostic or therapy.

**EIR-Table 1**

**BodiGuide Anklet (Leg Edema Monitor)**

**Company Name:** BodiGuide, Inc.

**Description:** BodiGuide has developed the first leg-edema monitoring system for heart failure patients. The BodiGuide Anklet automatically measures ankle circumference, which is the most direct and accurate way of quantifying fluid retention. It gives heart failure patients a worry-free way to improve self-care and inform their doctor of the need for medical attention to prevent emergency hospitalization.

Quantification of leg edema using continuous measurement of ankle circumference offers multiple advantages over the periodic capture of daily weight readings: increased patient compliance and confidence, improved self-care, and more proactive medical attention earlier in the window of intervention.

For patients and caregivers who struggle to consistently monitor fluid retention using a weight scale, the BodiGuide Anklet provides a continuous and accurate measurement of fluid loading and highlights the connection between increased ankle swelling and salt intake or lack of medication adherence.

For cardiologists and clinicians who need a reliable feedback mechanism to facilitate diuretic dosing or to determine the efficacy of a prescribed treatment, the BodiGuide Anklet allows the provider to easily obtain reliable data, focus on highly individualized, progressive treatment interventions, and achieve better patient outcomes, all while enhancing their feelings of professional satisfaction.

For hospitals and health systems that are looking for a cost-effective way to keep HF patients out of the hospital, the BodiGuide Anklet is a low-cost method of generating patient information that is needed for early intervention and the prevention of hospitalization.

BodiGuide’s founders have extensive experience in the medical device and pharmaceutical industries. They also have personal family experience with heart failure and therefore bring a deep understanding of the multi-dimensional challenges associated with heart-failure caregiving, patient self-care and cardiology.

**EIR-Table 2**

**CardioID**

**Company Name:** General Prognostics (GPx)

**Description:** BodiGuide General Prognostics (GPx) is a venture backed digital therapeutics company that is pioneering Bloodless Blood Tests by leveraging AI to calibrate wearable-collected digital biomarkers with vital blood biomarkers, to deliver clinically actionable information about heart failure (HF) patient status on a timely and cost-effective basis. This vital information will help to optimize Guideline Directed Medical Therapy (GDMT), and reduce HF readmissions.

Our first product, CardioID, provides deep and actionable insight to HF clinicians by combining the convenience of non-invasive biomarkers with accuracy of the gold standard measure of HF patient status, the blood-biomarker NT-proBNP. Non-invasive biomarkers collected by our peripherals are scanned by our Prediction Engine which then predicts significant changes in NT-proBNP without a drop of blood. If a significant change in NT-proBNP, and thus, patient status is predicted, the physician is notified to act. Timely intervention by the clinician, for example adjustment of patient diuretics, has been shown to stabilize patient condition and avoid expensive and deadly hospital readmissions.

**EIR-Table 3**

**Non-blood contacting, biventricular cardiac assist device**

**Company Name:** CorInnova, Inc.
**Description:** CorInnova is a preclinical company developing a non-blood contacting biventricular cardiac assist device for the treatment of heart failure that would treat the 40% of patients who cannot use existing devices, improving health equity. The device also eliminates the many adverse events associated with existing cardiac assist devices due to blood contact. Initially targeting the fast-growing short-term cardiac assist market (up to 5 days' use) and will expand addressable market by 50% to $6B+. Minimally invasive device deploys within the pericardial sac, surrounds both ventricles and gently compresses both ventricles to recover the heart. Medtech Innovator, Cohort 2022.

**EIR-Table 4**

**REN-001**

**Company Name:** Renovacor Inc.

**Description:** Renovacor’s mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.
Exhibitor Floorplan + Directory at a Glance

715  Abbott
302  ABIOMED
104  Alnylam Pharmaceuticals, Inc.
129  American Association of Heart Failure Nurses
226  American College of Cardiology
127  American Heart Association
820  American Regent, Inc.
232  American Society of Echocardiography
203  AstraZeneca
821  AstraZeneca/Ionis Medical Affairs
224  BioVentrax, Inc
135  BMS Medical Affairs
234  Bodyport Inc
719  Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC
817  Boston Scientific
116  Bristol Myers Squibb
110  CardioSignal Inc
228  Cardiovascular Clinical Sciences
815  CareDx, Inc.
721  CMP Pharma
827  Cormeum
801  CVRx
501  Cytokinetics Incorporated
811  Daiichi Sankyo, Inc.
823  Daxor Corporation
920  Endotronix
316  GETINGE
227  Houston Shock Symposium
507  Impulse Dynamics
930  Innovaccer Inc.
233  Inova Heart and Vascular Institute
922  Invitae
229  Jant Pharmacal Corporation
326  Lantheus
928  Lexicon Pharmaceuticals, Inc.
314  Medtronic
301  Merck & Co., Inc.
822  Natera
315  Novartis Pharmaceuticals Corporation
207  Nuveilis, Inc.
910  OM1
829  One Lambda, Inc., A Thermo Fisher Scientific Brand
729  Paragonix Technologies

701  Pfizer, Inc.
830  PhysioFlow/Manatec Biomedical
914  physIQ
826  Rhythm Science Inc
324  Sarfez Pharmaceuticals, Inc.
308  scPharmaceuticals
926  Sensible Medical
328  Ultromics
125  University of Maryland School of Pharmacy
916  V-Wave Inc
225  VisCardia Inc.
727  Vyaira Medical
206  ZOLL
T1  BodiGuide Inc. - Emerging Innovations Row 1
T2  General Prognostics (GPx) - Emerging Innovations Row 2
T3  CorInnova, Inc. - Emerging Innovations Row 3
T4  Renovacor Inc. - Emerging Innovations Row 4
Exhibitor Details - Descriptions

**Abbott – Booth #715**
**Description:** Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Connect with us at [www.abbott.com](http://www.abbott.com).

**ABIOMED – Booth #302**
**Description:** Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: [www.abiomed.com](http://www.abiomed.com).

**Alnylam Pharmaceuticals, Inc. – Booth #104**
**Description:** Alnylam is leading the translation of RNA interference into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Learn more: [www.alnylam.com](http://www.alnylam.com).

**American Association of Heart Failure Nurses – Booth #129**
**Description:** AAHFN is a specialty organization dedicated to advancing nursing education, clinical practice, and research to improve heart failure patient outcomes. Heart failure is our exclusive interest and passion. We unite the full spectrum of nurses and other health professionals. We welcome and value all professionals involved in heart failure care.

**American College of Cardiology – Booth #226**
**Description:** ACC’s Heart Failure Accreditation applies a holistic approach to the assessment, treatment, and management of the HF population and implements evidence-based and guideline-driven practices, process improvement, and performance measurements across the continuum of care. It improves the effectiveness of each decision point while safeguarding patient care and safe discharge.

**American Heart Association – Booth #127**
**Description:** When medical professionals apply up-to-date evidence-based treatment guidelines, patient outcomes improve. That’s the truth behind the drive for continuous quality improvement. American Heart Association’s® Quality Outcomes Research and Analytics (QORA) has a comprehensive suite of programs that can help you advance farther and faster in the quest for ever-better care.

**American Regent, Inc. – Booth #820**
**Description:** American Regent develops, manufactures and supplies high-quality sterile injectables for healthcare providers and their patients. Our growing business is comprised of generic and branded specialty injectables, as well as leading branded IV iron therapies.

**American Society of Echocardiography – Booth #232**
**Description:** ASE is the largest global organization for cardiovascular ultrasound imaging. We serve physicians, sonographers, nurses, veterinarians, and scientists. We are the leader and advocate for healthcare professionals practicing echocardiography, setting practice standards and guidelines for the field.

**AstraZeneca – Booth #203**
**Description:** AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries.

**AstraZeneca/Ionis Medical Affairs – Booth #821**
**Description:** AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries.
Exhibitor Details - Descriptions

BioVentrix, Inc. – Booth #224
Description: BioVentrix, Inc., is a privately held medical device company headquartered in San Ramon, California. The Company’s mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy. BioVentrix's Revivent TC™ system received the CE Mark and is currently pending FDA approval in the United States.

BMS Medical Affairs– Booth #135
Description: Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Bodyport Inc – Booth #234
Description: Bodyport is a digital therapeutics company on a mission to address complex chronic conditions. The 510(k) cleared Bodyport Cardiac Scale™ enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess heart function and fluid status in the same step they measure their weight.

Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC – Booth #719
Description: Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC look forward to the opportunity to share clinical information on our products. For additional information regarding Jardiance® (empagliflozin) tablets, visit us at https://pro.boehringer-ingelheim.com/us/products/jardiance/. For all other inquiries, contact us at www.bi-druginforequest.com.

Boston Scientific – Booth #817
Description: Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices. For more than 40 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties.

Bristol Myers Squibb – Booth #116
Description: Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

CardioSignal Inc – Booth #110
Description: CardioSignal is a health technology company on a mission to improve early detection of heart disease. The company is developing a unique motion sensor technology that is accessible with most modern smartphones. This patented technology enables a digital cardiac biomarker, and it is based on a decade of academic research.

Cardiovascular Clinical Sciences – Booth #228
Description: For scientific understanding, responsiveness, and operational rigor to get products to the next milestone, look to CCS. From Phase I to pivotal Phase III trials and core imaging laboratory services, our experienced team navigates the most complex studies and can bring products to market faster to improve patients’ heart health.

CareDx, Inc. – Booth #815
Description: Leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. Offering testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.

CMP Pharma – Booth #721
Description: CMP Pharma’s portfolio of FDA-approved ready-made oral liquid products: Norliqva® (Amlodipine) Oral Solution, 1mg/mL, is the first FDA-approved liquid solution for hypertension in adults and children 6 years and older. CaroSpir® (Spironolactone) Oral Suspension, 25 mg/5mL is the first and only FDA-approved oral suspension of the potassium-sparing diuretic spironolactone.
Cormeum – Booth #827
Description: Empower, educate and engage your patients by recommending the Cormeum app and providing them with the opportunity to self-manage their heart failure. The Cormeum app was designed to make managing HF easy by enabling patients to track their daily, weekly and monthly metrics. Check us out at www.cormeumapp.com.

CVRx – Booth #801
Description: Barostim™ is the first medical technology approved by the FDA that uses neuromodulation to improve the symptoms of heart failure. It works by electrically stimulating carotid baroreceptors which increases baroreflex sensitivity, rebalances the autonomic nervous system and improves heart failure symptoms.

Cytokinetics Incorporated – Booth #501
Description: Cytokinetics is focused on discovering, developing and commercializing potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology, we are developing drug candidates specifically engineered to impact muscle function and contractility.

Daiichi Sankyo, Inc. – Booth #811
Description: Daiichi Sankyo, Inc., is focused on the development of oncology and specialty medicines. Medicines approved in the U.S. include therapies for metastatic breast cancer, gastric cancer, tenosynovial giant cell tumor, IV iron therapy, thrombosis, stroke risk reduction and more.

Daxor Corporation – Booth #823
Description: Daxor is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, quantification of blood volume status and composition.

Endotronix – Booth #920
Description: Endotronix’s integrated platform provides comprehensive, reimbursable health management innovations for patients suffering from advanced heart failure (HF). The Cordella™ Heart Failure System includes a cloud-based disease management system and at-home hemodynamic management with an implantable wireless pulmonary artery pressure sensor for early detection of worsening HF. Learn more at www.endotronix.com.

GETINGE – Booth #316
Description: With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, life science, and Applikon bioreactor systems. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

Houston Shock Symposium – Booth #227
Description: The Annual Houston Shock Symposium is a collaborative event between UTHealth and Memorial Hermann Hospital and has been continuously endorsed by HFSA. Join us in April 2023, and share thoughts, best practices and unique cases.

Impulse Dynamics – Booth #507
Description: CCM® therapy is a breakthrough treatment proven to help many people with heart failure feel better and reduce their symptoms. It’s the first therapy designed to improve contractility of the heart, allowing more oxygen-rich blood to the body. Before its FDA-approval, eligible patients had few effective options available to them.

Innovaccer Inc. – Booth #930
Description: Innovaccer Inc. is a leading healthcare technology company committed to helping healthcare care as one. The Innovaccer® Health Cloud unifies patient data across systems and helps healthcare organizations rapidly develop modern applications that improve clinical, operational, and financial outcomes.

Inova Heart and Vascular Institute – Booth #233
Description: Inova Heart and Vascular Institute, led by
Christopher O’Connor, MD, is based in Northern Virginia. We partner with pharmaceutical and medical device companies to investigate novel therapies through the work of our cardiac, vascular and pulmonary physicians, with a focus on improving patient outcomes. Capabilities cover a full spectrum of cardiovascular care.

Invitae – Booth #922
Description: Invitae’s mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for everyone. We offer high-quality, affordable testing across all of life’s stages. Visit www.invitae.com.

Jant Pharmacal Corporation – Booth #229
Description: The Response RAMP NT-proBNP provides rapid, accurate diagnosis and assessment of CHF in about 15 minutes. Diagnostic accuracy is comparable to the Roche Elecsys proBNP. The RAMP system can run 2-6 tests concurrently and is quantitative and self-calibrating. Other CV tests include Troponin I, Myoglobin and CK-MB.

Lantheus – Booth #326
Description: With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. For more information, visit www.lantheus.com.

Lexicon Pharmaceuticals, Inc. – Booth #928
Description: Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using this patient-driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patients’ lives.

Medtronic – Booth #314
Description: We lead global healthcare technology. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people. Transforming the lives of two people every second.

Merck & Co., Inc. – Booth #301
Description: At Merck, we use the power of leading-edge science to save and improve lives around the world. We’ve been at the forefront of research, bringing forward medicines, vaccines, and innovative health solutions for the world’s most challenging diseases.

Natera – Booth #822
Description: Developed by our trusted legacy and experience from performing over 3 million cfDNA tests, Natera provides advanced DNA technology that enables transplant care teams to deliver quality, personalized care.

Novartis Pharmaceuticals Corporation – Booth #315
Description: Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We rank among the world’s top companies investing in research and development, and our products reach nearly 800 million people globally.

Nuwellis, Inc. – Booth #207
Description: Nuwellis is committed to transforming fluid management care through the development of solutions that are clinically proven, safe, and reliable. The Aquadex SmartFlow® System, our ground-breaking and proven ultrafiltration solution, gently removes fluid and restores balance to patients suffering from fluid overload.

OM1 – Booth #910
Description: Specializing in chronic conditions, OM1 is re-imagining real-world data and evidence by developing electronically connected networks of clinicians and health data. Leveraging its extensive cardiology clinical network, premium HF dataset, and AI platform, OM1 offers access to longitudinal patient journeys and outcomes for rapid and in-depth analyses, research, and decision support.
One Lambda, Inc., A Thermo Fisher Scientific Brand – Booth #829  
**Description:** A global leader in transplant diagnostics, One Lambda is committed to improving the lives of patients worldwide by driving innovation and delivering quality products. Our comprehensive product portfolio includes a broad range of industry leading antibody detection and monitoring solutions, HLA Typing products, laboratory instrumentation and software, and industry-leading customer support.

Paragonix Technologies – Booth #729  
**Description:** Paragonix Technologies designs, produces, and sells organ transportation devices that safeguard organs during the journey between donor and recipient. Our award-winning devices mitigate risk in high stakes environments. Paragonix systems incorporate clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide physical and thermal protection.

Pfizer, Inc. – Booth #701  
**Description:** At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

PhysioFlow/Manatec Biomedical – Booth #830  
**Description:** The PhysioFlow range of handheld and noninvasive cardiac output measuring systems is fully validated at rest and during exercise (FDA approved). They enable early detection of cardiovascular abnormalities (systolic and diastolic), risk stratification of HF patients and drug therapy optimization for reducing rehospitalization rates and improving outcomes.

physIQ – Booth #914  
**Description:** physIQ delivers personalized medical predictions that improve patient outcomes. By combining proprietary AI and wearable biosensors to continuously monitor patients in real-world settings, physIQ is advancing medicine by enabling proactive detection of physiological decompensations, improving safety and efficacy of new therapies and time to market, and delivering personalized clinical interventions.

Rhythm Science Inc – Booth #826  
**Description:** At RhythmScience Inc. we believe that the medical device revolution in cardiology will prevent disease progression, if the data is used properly. We are a services and software company focused on making cardiology data useful for providers to prevent major cardiovascular events.

Sarfez Pharmaceuticals, Inc. – Booth #324  
**Description:** Soaanz is a novel torsemide formulation that releases the drug slowly and induces diuresis and natriuresis comparable to generic torsemide, but without causing acute excessive urination. Thus, SOAANZ may help heart failure patients with symptoms of overactive bladder, especially those whose symptoms get worse with the use of loop diuretics.

scPharmaceuticals – Booth #308  
**Description:** scPharmaceuticals is a pharmaceutical company focused on developing and commercializing innovative solutions to enhance the potential of outpatient care.

Sensible Medical – Booth #926  
**Description:** Discover ReDS™ Pro -Remote Dielectric Sensing - for Absolute, Accurate, and Actionable lung fluid measurements for heart failure patients. Easy to use in the hospital, clinic or other skilled nursing facility. Provides non-invasive readings in 45 Seconds. THE advanced technology to monitor patient lung fluid and reduce cardiovascular readmissions.

Ultromics – Booth #328  
**Description:** Ultromics’ AI-powered platform, EchoGo, is revolutionizing echocardiography. Proven to predict patient outcomes, this groundbreaking solution automates complex analysis through a secure cloud connection. With unprecedented accuracy and zero variability, Ultromics empowers providers with superior heart disease detection and risk stratification.

University of Maryland School of Pharmacy – Booth #125  
**Description:** Exhibit for Cardiology and Pain/palliative care education.
V-Wave Inc – Booth #916
Description: V-WAVE was established in Israel in 2009 with a focus on developing percutaneous implantable technologies for patients with chronic heart failure. Technology designed by V-Wave, highlighted by its Ventura® Interatrial Shunt System, was designed to help heart failure patients with relief of symptoms, reduced hospitalizations, and improved quality of life.

VisCardia Inc. – Booth #225
Description: VisCardia developed Synchronized Diaphragmatic Stimulation (SDS®), deployed through a proprietary, implantable device (VisONE®), improves the heart’s performance by recruiting the diaphragm as a type of circulatory assist mechanism. This approach acts as a direct mechanism of mechanical cardiac assistance without increasing cardiac demand or having a negative impact on respiration.

Vyaire Medical – Booth #727
Description: Cardiopulmonary Exercise Testing CPET metabolic cart, with ECG, BP, and bike and treadmill modalities.

ZOLL – Booth #206
Description: ZOLL Respecardia and Itamar - both divisions from ZOLL partnering together to provide Sleep Apnea screening, solutions and education. WatchPAT One is Itamar’s one time use home sleep apnea test. Respecardia’s remede system is an implantable device to help treat sleep apnea.
SEE YOU IN 2023!

HFSA 2023
ANNUAL SCIENTIFIC MEETING
WHERE HEART FAILURE TEAMS GATHER

October 6 - October 9
Huntington Convention Center of Cleveland

Cleveland, Ohio